Nueli Capital

Nueli Capital (纽尔利资本) is a Chinese fund that has surfaced in elsewhere's corpus primarily as a co-investor and buyer in secondary transactions. In late 2023 it partnered with SoftBank China Capital on a restructuring S deal, becoming the sole LP in a new RMB continuation fund that held three remaining portfolio companies while SoftBank stayed on as GP . The fund has also taken lead positions in growth rounds: in May 2024 it co-led Xingji's Series B, a digital-implementation EDA company, alongside Vertex Growth , and it has re-upped as an existing shareholder in Aureka Biotechnologies' successive A and A+ rounds for generative antibody drug development through late 2025 and into 2026 . Its activity pattern suggests a mix of direct venture co-investments and LP-secondaries, though elsewhere's coverage is deal-specific rather than profile-deep.